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Abstract
A complex of the Adenovirus (Ad) early region 1b 55-kDa protein (E1b-55kDa) and the early region 4 ORF6 34-kDa protein (E4-34kDa)
promotes viral late RNA accumulation in the cytoplasm while inhibiting the transport of most newly synthesized cellular mRNA. The E4
ORF3 11-kDa protein (E4-11kDa) functionally compensates for at least some of the activities of this complex. We find that the same large
central region of E4-34kDa that is required for proteasome-mediated degradation of p53 (J. Virol. 75, (2001) 699–709) is also required to
promote viral late gene expression in a complementation assay. E4-34kDa does not promote late gene expression in complementation assays
performed in the presence of proteasome inhibitors. A proteasome inhibitor also dramatically reduced late gene expression by a virus that
lacks the E4-11kDa gene and therefore relies on E4-34kDa for late gene expression. Our results suggest that E4-34kDa activity in promoting
late gene expression depends on the proteasome.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Adenovirus (Ad) DNA replication, nuclear and cytoplas-
mic late mRNA accumulation, late viral protein synthesis,
and virus particle assembly depend on gene products from
early regions 1b (E1b) and 4 (E4) (Babiss et al., 1985;
Bridge et al., 1993; Halbert et al., 1985; Pilder et al., 1986).
Single deletions of either E4 ORF3 encoding an 11-kDa
protein (E4-11kDa) or E4 ORF6 encoding a 34-kDa protein
(E4-34kDa) have only modest effects on virus growth and
each are sufficient to substitute for the whole E4 region
during Ad lytic infection (Bridge and Ketner, 1989; Huang
and Hearing, 1989).
The E4-34kDa and E1b-55kDa proteins from a complex
in infected cells (Sarnow et al., 1984) that is important for
promoting viral late gene expression. This complex acts
posttranscriptionally to facilitate the accumulation of viral
late mRNAs while inhibiting the nucleocytoplasmic trans-
port of newly synthesized cellular mRNA (Babiss et al.,
1985; Bridge and Ketner, 1990; Halbert et al., 1985; Huang
and Hearing, 1989; Pilder et al., 1986). The E4-34kDa/E1b-
55kDa complex also promotes the degradation of the tumor
suppressor p53 (Querido et al., 1997, 2001a, b) and the
Mre11/Rad50/NBS1 components of the mammalian DNA
repair system in infected cells (Stracker et al., 2002). The
E4-34kDa/E1b-55kDa complex interacts with a cellular cul-
lin-containing E3 ubiquitin ligase which subsequently
polyubiquitinates p53 and targets it for proteasome-medi-
ated degradation (Harada et al., 2002; Querido et al.,
2001a).
A computer generated model for the structure of the
E4-34kDa protein described by Flint and colleagues sug-
gested the existence of a core classic triose phosphate
isomerase barrel-like structure and an unusual binuclear
zinc coordination structure involving histidine and cysteine
residues (Brown et al., 2001). In support of this model,
E4-34kDa is able to bind zinc and E4-34kDa proteins with
point mutations in several conserved histidine and cysteine
residues lost the ability to bind E1b-55kDa, degrade p53,
and promote expression of late viral genes (Boyer and
Ketner, 2000). The presence of a C-terminal amphipathic
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-helix characterized previously (Orlando and Ornelles,
1999) was predicted in the computer model. A proline
substitution which disrupts the integrity of the C-terminal
amphipathic -helix renders the E4-34kDa protein unable to
direct the nuclear localization of E1b-55kDa, support virus
growth (Orlando and Ornelles, 1999), promote p53 degra-
dation (Nevels et al., 1997; Querido et al., 2001b), or trans-
form BRK cells in cooperation with E1a and E1b (Nevels et
al., 1997). Therefore, integrity of both structural motifs is
important for many functions of the E4-34kDa protein.
A role for the E4-34kDa/E1b-55kDa complex in selec-
tive RNA export has been suggested since mutant viruses
lacking the E4-34kDa and E1b-55kDa genes show reduced
levels of late viral mRNA accumulation in the cytoplasm
and fail to prevent host mRNA transport. Both the E4-
34kDa and the E1b-55kDa proteins have leucine-rich nu-
clear export signals (NES) of the HIV-1 Rev type and
shuttle between the nucleus and cytoplasm during Ad in-
fection (Dobbelstein et al., 1997; Dosch et al., 2001; Kratzer
et al., 2000; Rabino et al., 2000). Leucine-rich NESs utilize
the cellular CRM1 export pathway (Fornerod et al., 1997;
Fukuda et al., 1997) and leptomycin B, a specific inhibitor
of the CRM1 export pathway (Kudo et al., 1998), prevents
the cytoplasmic accumulation of E1b-55kDa during Ad
infection (Dosch et al., 2001). However, a role for CRM1 in
E4-34kDa export remains unresolved (Dobbelstein et al.,
1997; Dosch et al., 2001; Rabino et al., 2000; Weigel and
Dobbelstein, 2000). E1b-55kDa also has the ability to bind
RNA (Horridge and Leppard, 1998), suggesting a model in
which the E4-34kDa/E1b-55kDa complex could access the
cellular CRM1 export pathway and preferentially transport
viral mRNA bound by E1b-55kDa. However, we have pre-
viously shown that an E4-34kDa protein with leucines sub-
stituted with alanines in the NES complements the late gene
expression defect of an E4 mutant as well as the wild-type
protein, and leptomycin B does not prevent Ad5 viral late
gene expression (Rabino et al., 2000). These results sug-
gested that NES activity is not essential for the function of
the E4-34kDa protein in promoting late gene expression.
Since we did not identify a critical role for the E4-34kDa
NES in promoting viral late gene expression, we undertook
a genetic analysis of the protein to identify other regions of
the protein that were important for its function. Querido et
al. (2001a,b) mapped regions of the E4-34kDa protein im-
portant for interacting with E1b-55kDa and targeting p53
for ubiquitination and proteasome-mediated degradation.
Here we show that these same regions are also critical for
the ability of E4-34kDa to complement late gene expres-
sion. The ability of E4-34kDa to promote viral replication
and late gene expression depended on functional protea-
somes and this requirement was conserved among several
E4-34kDa proteins from other human Ad serotypes. Inter-
estingly, although promotion of late gene expression by the
E4-34kDa protein was proteasome-dependent, the protea-
some inhibitor MG132 did not dramatically affect late gene
expression of viruses with an intact E4-11kDa gene. Our
results suggest that the ability of the E4-34kDa/E1b-55kDa
complex to promote degradation of target proteins via the
proteasome is important for the efficient transition of in-
fected cells to the late phase, in the absence of the redundant
functions of E4-11kDa.
Results
Complementation of H5dl1011 late gene expression by
Ad5 E4-34kDa mutants and Ad E4-34kDa variants
We used a complementation assay to determine what
regions of the E4-34kDa protein are important for promot-
ing viral late gene expression. Fig. 1 shows the location of
the E4-34kDa mutations that we studied. HeLa cells were
transfected with increasing amounts of wild-type pcDNA
E4-34kDa plasmid to generate a standard curve of wild-type
protein expression with which to compare cells transfected
with mutant E4-34kDa constructs. At 24 h posttransfection,
cells were infected with 20 fluorescence forming units
(FFU)/cell of the Ad5 E4-deletion virus H5dl1011. This
multiplicity of infection ensured that greater than 90% of
the cells were infected as determined by detection of the
early 72-kDa DNA binding protein at 24 h postinfection
(hpi) (data not shown). Cell extracts from transfected/in-
fected cultures were collected at 24 hpi and subjected to
Western blotting using antibodies against E4-34kDa and the
late proteins penton and fiber.
A representative Western blot with a standard curve of
wild-type E4-34kDa expression and two C-terminal dele-
tions (dl277–294 and dl271–294) is shown in Fig. 2A.
H5dl1011 was defective for viral DNA replication (data not
shown) and expression of late proteins penton and fiber
when no E4-34kDa plasmid was transfected (Fig. 2A,
mock). Increasing amounts of wild-type E4-34kDa plasmid
resulted in more E4-34kDa protein expressed (Fig. 2A, top)
Fig. 1. Schematic of the Ad5 E4-34kDa protein and E4-34kDa mutants
used in this study. The positions of the NES (nuclear export signal), CCR
(conserved cysteine-rich motif), and amphipathic -helix motifs are indi-
cated by labeled black boxes. The names of the E4-34kDa mutants indicate
the amino acids (aa) deleted from the full-length protein. The black bars by
each mutant represent the regions of the protein present for each mutant.
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and correspondingly more of the late proteins penton and
fiber were expressed in those cultures (Fig. 2A, bottom).
The E4-34kDa mutant dl277–294 complemented late gene
expression about half as well as wild-type E4-34kDa when
late protein levels were normalized for the amount of E4-
34kDa produced from the transfected constructs. No late
proteins were detected in dl271–294-transfected/H5dl1011-
infected cells, indicating that this E4-34kDa mutant did not
complement late gene expression (Fig. 2A).
To determine the percentage of wild-type E4-34kDa
complementation for each mutant shown in Fig. 2B, we
used phosphorimager analysis to quantify the amount of
E4-34kDa and penton and fiber proteins expressed. Levels
of late proteins were normalized for the amount of E4-
34kDa expressed to determine the percentage of wild-type
complementation achieved by each mutant; wild-type E4-
34kDa complementation was set at 100% (see Materials and
methods). A standard curve of wild-type E4-34kDa and late
protein expression was used in every replicate experiment to
account for E4-34kDa expression differences between the
wild-type and E4-34kDa mutants. An E4-34kDa protein
lacking 20 amino acids from the N-terminus (dl1–20) was
able to promote late gene expression as well as wild-type
but a larger deletion of 55 amino acids (dl1–55) was defec-
tive for complementation (Fig. 2B). Since deletion of the
first 55 amino acids of E4-34kDa produces a protein that is
unable to form a complex with E1b-55kDa (Querido et al.,
2001b; Rubenwolf et al., 1997), our results confirm the
importance of this complex for promoting viral late gene
expression. An E4-34kDa protein with 17 amino acids de-
leted from the C-terminus (dl277–294) was only two-fold
reduced (50% of wild-type) for complementation, and sur-
prisingly, removal of only six more amino acids (dl271–
294) rendered the E4-34kDa protein unable to complement
late gene expression (Figs. 2A and B). These data show that
the region between amino acids 20 and 276 is important for
the ability of E4-34kDa to promote viral late gene expres-
sion.
We also tested E4-34kDa proteins from other human
Ad serotypes for complementation. Many regions of the
E4-34kDa protein are conserved between serotypes such
as the histidine and cysteine residues predicted to coor-
dinate zinc (Boyer and Ketner, 2000) and the amphi-
pathic -helix (Orlando and Ornelles, 1999). The E4-
34kDa proteins from Ad9, Ad12, and Ad40 have 58, 51,
and 39% amino acid identity, respectively, when aligned
in a BLAST analysis with the Ad5 protein. All Ad E4-
34kDa proteins were epitope tagged on the C-terminus
with the influenza hemagglutinin amino acid sequence
(YPYDVPDYA) to facilitate their detection. The Ad9,
Ad12, and Ad40 E4-34kDa proteins were able to rescue
the late gene expression defect of H5dl1011 as deter-
mined by the presence of penton and fiber proteins in
Western blots of protein extracts prepared from trans-
fected/infected cultures (Fig. 2C). This suggests that E4-
34kDa proteins from several human serotypes have con-
served the ability to promote late gene expression.
Fig. 2. Complementation of late gene expression by Ad5 E4-34kDa dele-
tion mutants and E4-34kDa from other human Ad serotypes. (A) HeLa
cells were either mock transfected or transfected with increasing amounts
(0.25–2.0 g) of the wild-type Ad5 E4-34kDa expression construct or 2.0
g of the E4-34kDa mutants (dl277–294 and dl271–294) for 24 h. Cells
were then infected with 20 FFU/cell of H5dl1011 and cell extracts were
collected at 24 hpi. We used 60 and 30 g of total proteins for SDS–PAGE
for detection of E4-34kDa and penton/fiber, respectively. Mouse mono-
clonal antibody RSA3 was used for detection of wild-type and C-terminal
deletions of E4-34kDa (top) and a rabbit polyclonal antiserum raised
against penton and fiber was used to detect viral late proteins (bottom). (B)
Quantification of complementation by N- and C-terminal deletions of Ad5
E4-34kDa. HeLa cells were either mock transfected or transfected for 24 h
with increasing amounts (0.25–2.0 g) of the wild-type Ad5 E4- 34kDa
expression construct or 2.0 g of the E4-34kDa mutants (dl1–20, dl1–55,
dl271–294, dl277–294) and then infected with 20 FFU/cell of H5dl1011
for 24 h. Cells extracts from transfected/infected cultures were subjected to
Western blotting and the amount E4-34kDa and penton and fiber proteins
expressed was determined by phosphorimager analysis. A standard curve
of wild-type E4-34kDa complementation was used to quantify the percent-
age of wild-type complementation achieved by each E4-34kDa mutant for
every experiment (see Materials and methods). Wild-type complementa-
tion was set at 100%. The average  the standard deviation (SD) for three
experiments for each E4-34kDa mutant is shown. (C) HeLa cells were
either mock transfected or transfected with 1.0 and 2.0 g Ad5 and 2.0 g
of Ad9, Ad12 (left) or 1.0 g of Ad5 or Ad40 E4-34kDa expression
constructs (right) for 24 h. At 24 h posttransfection, cells were infected
with 20 FFU/cell of H5dl1011 for 24 h. Cells extracts were collected and
30 g of total protein was subjected to SDS–PAGE and Western blotting
for the detection of penton and fiber.
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The central region of the E4-34kDa protein is important
for complementing Ad late gene expression independent
of its role in degrading p53
Mapping studies of the Ad5 E4-34kDa protein by
Querido et al. (2001b) described a large central region of the
E4-34kDa protein (amino acids 44–274) that was important
for promoting the degradation of p53 via a complex with
E1b-55kDa and an E3 ubiquitin ligase. The proteasome
inhibitors MG132 and lactacystin prevent E4-34kDa/E1b-
55kDa-mediated degradation of p53 (Querido et al.,
2001a,b). Interestingly, N- and C-terminal deletions that did
not complement late gene expression in our assay over-
lapped with regions described by Querido et al. (2001b)
required for p53 turnover (amino acids 44– 274). To deter-
mine if there is a correlation between regions of the protein
needed to promote p53 degradation and viral late gene
expression, we tested several small internal E4-34kDa de-
letions used by Querido et al. (2001b) to characterize the
importance of the central portion of the protein for p53
degradation. Two deletion mutants in the N- terminus,
dl35–43 and dl49–64, and two C-terminal deletion mu-
tants, dl249–274 and dl275–294 (Fig. 1), were tested for
complementation in HeLa cells as described for Fig. 2B.
The dl35–43 and dl275–294 mutants, that degrade p53,
were reduced two-fold or less for complementation (Fig.
3A). In contrast, mutants that do not degrade p53, dl49–64,
and dl249–274 were unable to rescue viral late gene ex-
pression of H5dl1011 in HeLa cells (Fig. 3A). Other inter-
nal E4-34kDa deletions tested by Querido et al. (2001b) that
could not degrade p53 (dl123–126 and dl154–180) also
failed to complement late gene expression in our assay (data
not shown). These results show that regions of the E4-
34kDa protein important for promoting p53 degradation are
also needed to promote late gene expression.
HeLa cells express very low levels of p53 due to the
presence of the human papilloma virus 18 E6 protein, which
targets p53 for proteasome-mediated degradation (Scheffner
et al., 1990). Several groups have shown that the replication
efficiency of E1b-55kDa mutant viruses does not correlate
with p53 status, suggesting that neutralizing p53 activity is
not critical for Ad lytic infection (Goodrum and Ornelles,
1998; Harada and Berk, 1999). Thus, it was somewhat
surprising that regions of the E4-34kDa protein important
for p53 degradation were also important for promoting late
gene expression. We tested the role of p53 status for E4-
34kDa function by performing the complementation assay
in a p53 null non-small lung carcinoma cell line, H1299. In
H1299 cells, H5dl1011 was still defective for viral late gene
expression when no plasmid was transfected (Fig. 3B,
mock). The same E4-34kDa mutants (dl35–43 and dl275–
294) that could degrade p53 and complement late gene
expression in HeLa cells could also complement late gene
expression in H1299 cells (Figs. 3A and B). Likewise,
E4-34kDa mutants that were unable to degrade p53 or
complement late gene expression in HeLa cells (dl49–64
and dl249–274) were also defective for late gene expression
in H1299 cells (Figs. 3A and B). This indicates that the
central region of the E4-34kDa protein is important for
complementing viral late gene expression independent of its
role in degrading p53.
Proteasome inhibitors prevent E4-34kDa from
complementing late gene expression
Recently Stracker et al. (2002) showed that Ad oncop-
roteins are able to disrupt the ability of cellular double-
strand break repair (DSBR) enzymes to form concatemers
of viral DNA genomes. The E4-34kDa/E1b-55kDa complex
and the E4-11kDa proteins are independently able to pre-
vent Ad genome concatemerization. The E4-11kDa protein
redistributes DSBR proteins away from viral replication
centers. The E4-34kDa/E1b- 55kDa proteins promote the
Fig. 3. Complementation by E4-34kDa internal deletions in HeLa and
H1299 (p53 null) cells. (A) HeLa cells were either mock transfected or
transfected with increasing amounts (0.25–2.0 g) of the wild-type Ad5
E4-34kDa expression construct or 1.0–2.0 g of the E4-34kDa mutants
(dl35–43, dl49–64, dl249–274, or dl275–294) for 24 h and subsequently
infected with 20 FFU/cell H5dl1011 for 24 h. Cell extracts were subjected
to SDS–PAGE and Western blotting. Wild-type E4-34kDa and dl35–43
were detected with E4 ORF6 C-terminal antibody 1807; wild-type E4-
34kDa, dl49–64, dl249–274, and dl275–294 were detected with RSA3.
Penton and fiber were detected as described in Fig. 2A. Phosphorimager
analysis was used to quantify the wild-type and mutant E4-34kDa and the
late proteins penton and fiber. A standard curve of wild-type E4-34kDa
complementation was used to quantify the percentage of wild-type comple-
mentation achieved by each E4-34kDa mutant for every experiment (see
Fig. 2B and Materials and methods). Wild-type E4-34kDa complementa-
tion was set at 100%. The average  SD from three experiments is shown
for each E4-34kDa mutant. (B) Complementation assay was done as
described for part A in H1299 cells, a p53-null lung carcinoma cell line.
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degradation of DSBR proteins; degradation is prevented by
the proteasome inhibitor MG132 (Stracker et al., 2002).
Therefore, a target for E4- 34kDa/E1b-55kDa-mediated
degradation includes DSBR enzymes in addition to p53. We
used the proteasome inhibitors MG132, lactacystin, and
clasto-lactacystin -lactone to investigate the role of the
proteasome for E4-34kDa function in complementation.
MG132 is a synthetic peptide that reversibly inhibits the
catalytic subunit of the proteasome as well as other pro-
teases such as cathepsins and calpains (Lee and Goldberg,
1996; Rock et al., 1994). Lactacystin is a naturally occurring
compound that rearranges to form clasto-lactacystin -lac-
tone in aqueous solutions. Clasto-lactacystin -lactone ir-
reversibly and specifically inhibits the proteasome (Fente-
any et al., 1995). MG132 and lactacystin were previously
shown to prevent Ad5 E4-34kDa/E1b-55kDa-mediated p53
degradation (Querido et al., 2001a,b). We first demonstrated
the effectiveness of these inhibitors by confirming that they
could prevent degradation of p53. HEK 293 cells, which
express E1a and E1b proteins (Graham et al., 1977), were
either cotransfected with pcDNA p53 and the wild-type Ad5
E4-34kDa expression plasmid or mock transfected. Trans-
fected cells were either not treated or treated from 24- 40 h
posttransfection with the proteasome inhibitors MG132,
lactacystin, or clasto- lactacystin -lactone. Cell extracts
were then analyzed by Western blotting for the amount of
p53. The HEK 293 cells had low levels of endogenous p53
(Fig. 4, lanes 1 and 2). p53 degradation was observed in
cells cotransfected with pcDNA p53 and Ad5 E4-34kDa
expression constructs (Fig. 4, compare lanes 3 with 5, and 8
with 9), as expected (Querido et al., 2001a,b). p53 degra-
dation was prevented in pcDNA p53/E4-34kDa cotrans-
fected cells cultured with 10 M of the proteasome inhib-
itors MG132, lactacystin, and clasto-lactacystin -lactone
(Fig. 4, lanes 6,7, and 10). MG132 did not significantly
affect endogenous or overexpressed p53 levels in the ab-
sence of the E4-34kDa protein (Fig. 4, compare lanes 1 with
2, and 3 with 4). The p53 protein is transcriptionally inac-
tive in HEK 293 cells due to the expression of Ad E1a and
E1b proteins in these cells (Grand et al., 1995). Transcrip-
tionally inactive p53 should not induce its negative regula-
tor MDM2 and will therefore not be targeted for protea-
some- mediated degradation by the normal cellular pathway
in HEK 293 cells. This is consistent with our observation
that proteasome inhibitors do not affect p53 levels in HEK
293 cells in the absence of the E4-34kDa protein.
We next investigated the effect of proteasome inhibitors
on E4-34kDa-mediated complementation of H5dl1011 late
gene expression. HeLa cells were transfected with an Ad5
E4-34kDa expression construct for 24 h. Transfected cells
were treated with 10 M MG132, lactacystin, or clasto-
lactacystin -lactone 5 h prior to infection with 20 FFU/cell
of H5dl1011 to ensure that proteasome activity was inhib-
ited at the time of infection. Infected cells were then treated
with proteasome inhibitors from 2–24 hpi as indicated.
Total cell extracts were analyzed by Western blotting for
expression of the late proteins penton and fiber. The Ad5
E4-34kDa protein was unable to complement H5dl1011 late
gene expression in cells cultured with MG132, lactacystin,
or clasto- lactacystin -lactone (Fig. 5A). Levels of the
early DNA replication protein E2-72kDa detected in in-
fected cultures treated with inhibitors were not reduced
compared to the levels seen in untreated H5dl1011-infected
cells (data not shown). This indicates that pretreatment of
cells with proteasome inhibitors did not interfere with
H5dl1011 infection or early gene expression. Complemen-
tation by the Ad9, Ad12, and Ad40 E4-34kDa proteins was
prevented by treatment with MG132 from 2–24 hpi (Fig.
5B). These results suggest that E4-34kDa requires func-
tional proteasomes for its activity in promoting late gene
expression and this requirement is conserved among E4-
34kDa proteins from other human adenoviruses. Comple-
mentation of H5dl1011 by the E4-34kDa protein was only
inhibited when transfected/infected cells were pretreated
with lactacystin and clasto-lactacystin -lactone. MG132
could still inhibit complementation when added to trans-
fected/infected cells directly after virus adsorption (2 hpi)
(Fig. 5B), but it failed to inhibit complementation when
added at 8 or 10 h postinfection (Fig. 5C). This indicates
that E4-34kDa function requires active proteasomes during
the early stages of infection.
Role of the proteasome in Ad replication and late gene
expression
Our results indicate that functional proteasomes are
needed during the early phase for E4-34kDa complementa-
tion and suggest that the E4-34kDa/E1b-55kDa complex
may promote efficient viral late gene expression by target-
ing proteins for proteasome-mediated degradation. Genetic
studies have shown that the Ad E4-11kDa protein can at
least partially compensate for the activity of the E4-34kDa/
E1b-55kDa complex in promoting late gene expression
(Bridge and Ketner, 1989; Huang and Hearing, 1989). Since
Fig. 4. p53 degradation by the Ad E4-34kDa/E1b-55kDa complex. HEK
293 cells were mock transfected (lanes 1 and 2) or cotransfected with 1 g
of pcDNA p53 and Ad5 E4-34kDa (lanes 5–7 and 9 and 10) for 24 h. The
pcDNA3.1() empty cloning vector was cotransfected with pcDNA p53 to
keep the amount of plasmid DNA constant in E4-34kDa-negative cultures
(lanes 3, 4, and 8). Cells were left untreated or treated from 24 to 40 h
posttransfection with 10 M of the proteasome inhibitors MG132 (lanes 2,
4, and 6), lactacystin (lane 7), or clasto-lactacystin -lactone (lane 10). Cell
extracts were collected and 100 g of total protein was subjected to
SDS–PAGE and Western blotting. Mouse monoclonal Ab1801 was used to
detect p53.
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there is no evidence that E4-11kDa requires functional pro-
teasomes for its activity, it is possible that these viral reg-
ulatory proteins promote late gene expression by protea-
some- dependent and -independent mechanisms. We tested
this by investigating the effect of inhibiting proteasome
activity on the replication and gene expression activity of
Ad5 and viral mutants lacking genes for E1b-55kDa, E4-
34kDa, or E4-11kDa.
We first studied the effect of adding the proteasome
inhibitor MG132 at different stages of Ad5 infection. Ad5-
infected HeLa cells were treated with 10 M MG132 from
2–14, 2–24, or 14–24 hpi. This concentration of MG132
was sufficient to prevent E4-34kDa/E1b-55kDa-mediated
degradation of p53 (see Fig. 4). Total DNA and proteins
were isolated from cells and the levels of viral DNA (Fig.
6A); early and late proteins (Fig. 6B) were determined by
Southern and Western blotting, respectively. Infected cells
treated with 10 M MG132 from 2–14 hpi were 6.5-fold
reduced for viral DNA accumulation (Fig. 6A), reduced
two-fold for E2-72kDa expression, and failed to produce
detectable levels of penton and fiber (Fig. 6B). However,
with longer MG132 treatments from 2–24 hpi, viral DNA
and late protein levels (penton and fiber) were only reduced
two-fold (Fig. 6A) and three-fold (Fig. 6B), respectively,
and E2-72kDa levels were unaffected (Fig. 6B). Therefore,
MG132 treatment delayed the onset of the late phase but did
not prevent viral replication and late gene expression.
MG132 had no effect on late gene expression if it was added
from 14 to 24 hpi (Fig. 6B), suggesting that the proteasome-
mediated functions of the E4-34kDa/E1b-55kDa complex
are most important during the early phase. This is consistent
with our observation that MG132 does not inhibit comple-
mentation by E4-34kDa when added at 8 or 10 hpi (see Fig.
5C).
We next tested the effect of MG132 treatment on late
gene expression by Ad mutants. H5dl110, H5dl1010, and
H5dl1006 lack the genes for the E1b-55kDa, E4-34kDa, and
E4-11kDa proteins, respectively (Bridge and Ketner, 1989,
1990). HeLa cells were infected with Ad5, H5dl110,
H5dl1010, and H5dl1006 and were either cultured from
2–24 hpi with 10 M MG132 or left untreated. Cell extracts
were subjected to Western blotting to determine the levels
of late proteins produced during these infections. Ad5,
H5dl110, and H5dl1010-infected cells were two- to three-
fold reduced for late protein levels when infected cells
cultured with MG132 were compared to untreated infec-
tions (Fig. 6C). However, cells infected with the mutant
H5dl1006, which fails to make the E4-11kDa protein,
showed dramatically reduced levels of viral late proteins in
the presence of MG132 even though early gene expression
was within two-fold of untreated levels (data not shown).
This indicates that a virus lacking an intact gene for the
E4-11kDa protein is much more dependent on functional
proteasomes to progress to the late phase than viruses that
make the E4-11kDa protein.
Discussion
We have performed a genetic analysis to identify regions
of the E4-34kDa protein that are important for late gene
expression. Analysis of a series of nested N- and C-terminal
truncations revealed that deleting amino acids 1–55 (dl1–
55) of the N-terminus and 271–294 (dl271–294) of the
C-terminus rendered the E4-34kDa protein unable to com-
plement H5dl1011 (Figs. 1 and 2). Previous investigators
have shown that dl1–55 fails to bind E1b-55kDa (Querido et
al., 2001b; Rubenwolf et al., 1997). Thus, our data indicate
that regions important for E1b-55kDa binding are also im-
portant for promoting late gene expression in a complemen-
tation assay (Fig. 2B). This is consistent with the idea that
E1b-55kDa and E4-34kDa mediate their activities in late
gene expression as a complex (Babiss et al., 1985; Bridge
and Ketner, 1990). Although dl271–294 retains the ability
to bind E1b-55kDa (Querido et al., 2001b; Rubenwolf et al.,
1997), it still fails to complement H5dl1011 (Figs. 2A and
B). This suggests that E1b-55kDa binding may be necessary
Fig. 5. Complementation by E4-34kDa in the presence of proteasome
inhibitors. (A) HeLa cells were either mock transfected or transfected for
24 h with the Ad5 E4-34kDa expression construct. Five hours prior to
infection with 20 FFU/cell of H5dl1011, cells were either treated with 10
M MG132, lactacystin, or clasto-lactacystin -lactone or left untreated.
DMSO without inhibitor was added to control cells. Equal amounts of total
cell extracts were subjected to SDS–PAGE and Western blotting for penton
and fiber. (B) HeLa cells were either mock transfected or transfected with
Ad5, Ad9, Ad12, and Ad40 E4-34kDa expression constructs for 24 h. Cells
were infected with 20 FFU/cell H5dl1011 for 24 h and either treated with
10 M MG132 from 2–24 hpi or left untreated. Western blot analysis was
performed as described in part A. (C) Ad5 E4-34kDa transfected and
H5dl1011-infected cells were treated with 10 M MG132 from 2, 8, and
10 hpi or left untreated. Cell extracts were collected at 24 hpi and analyzed
by Western blotting for the amount of penton and fiber.
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but not sufficient for complementation. Querido et al.
(2001b) used a series of deletions to map regions of the
E4-34kDa protein important for p53 degradation. We used
several of these internal deletions to further define regions
of E4-34kDa that are important for complementation. E4-
34kDa mutants that complement late gene expression to
within 50% of wild-type levels also efficiently degrade p53.
In contrast, mutants that fail to complement late gene ex-
pression do not degrade p53 (Fig. 3) (Querido et al., 2001b).
Thus, E4-34kDa amino acids 44–274 are important both for
both p53 degradation (Querido et al., 2001b) and for pro-
moting late gene expression in a complementation assay
(Figs. 1–3).
Several conserved structural motifs and protein-binding
sites are located in the central region of the E4-34kDa
protein, including the NES, a central histidine and cysteine-
rich region (CCR), and an amphipathic -helix (Fig. 1). We
have previously found that point mutations in the E4-34kDa
NES are not critical for complementing late gene expression
(Rabino et al., 2000) and an E1b-55kDa NES mutant pro-
motes late gene expression of a virus mutant deleted for the
E1b-55kDa gene as well as wild-type (Carter et al., submit-
ted for publication). Querido et al. (2001b) studied the same
E4-34kDa NES mutant and found that it did not affect the
ability of E4-34kDa to degrade p53. The E4-34kDa protein
is able to bind zinc (Boyer and Ketner, 2000) and conserved
cysteine and histidine residues predicted to coordinate two
zinc ions are likely to be critical for the tertiary structure of
the E4-34kDa protein (Brown et al., 2001). Single point
mutations of specific cysteine and histidine residues (C51,
H123, C124, H125, C126, C134, and H185) produced pro-
teins that retained the ability to bind p53, but were unable to
bind E1b- 55kDa or degrade p53. These mutants also failed
to complement late gene expression of an E4 mutant (Boyer
and Ketner, 2000). A proline insertion in the amphipathic
-helix produced an E4-34kDa protein that was defective
for promoting both late gene expression (Orlando and Or-
nelles, 1999) and p53 degradation (Querido et al., 2001b). A
less disruptive mutation in the amphipathic -helix, R248E,
had little effect on either activity (Orlando and Ornelles,
1999; Querido et al., 2001b; Rabino et al., 2000). Thus, the
results of several studies suggest a close correlation between
the ability of E4-34kDa to degrade p53 and its ability to
complement late gene expression.
Amino acids 44–274 are important for the ability of
E4-34kDa to promote p53 turnover via the proteasome.
Several proteasome inhibitors dramatically decreased
complementation by the Ad5 E4-34kDa protein, and the
E4-34kDa proteins from Ad9, Ad12, and Ad40 (Fig. 5). The
observation that complementation was prevented by inacti-
vating proteasomes with three different inhibitors (Fig. 5)
strongly suggests that E4-34kDa mediates its functions in
late gene expression via the proteasome. However, comple-
mentation studies done in the p53 null cell line, H1299,
suggest that p53 is unlikely to be the critical target for
E4-34kDa/E1b-55kDa activity (Fig. 3B). Other proteins tar-
geted by the E4-34kDa/E1b-55kDa complex for protea-
some-mediated degradation include the Mre11/Rad50/
NBS1 components of the DSBR system. E4-34kDa/E1b-
55kDa interfere with DSBR by degrading Mre11/Rad50/
NBS1, while the E4-11kDa protein relocalizes Mre11/
Rad50/NBS1 proteins away from viral replication centers
Fig. 6. Effect of MG132 on Ad replication and late gene expression. (A) HeLa cells were infected with Ad5 at 10 FFU/cell for 14 and 24 h or not infected
(hpi 0). Cells were treated with 10 M MG132 from 2–14 or 2–24 hpi. DMSO was added to untreated cells. Total DNA was isolated, digested with EcoRI,
and separated by agarose gel electrophoresis. Viral DNA was detected by Southern blotting with 32P-labeled Ad DNA probe. Phosphorimager analysis was
used detect and quantify the levels of Ad DNA. The arrows on the left indicate the expected positions of Ad5 DNA fragments upon digestion with EcoRI.
(B) HeLa cells were infected with Ad5 at 10 FFU/cell and treated with 10 M MG132 from 2–14, 2–24, or 14–24 hpi. DMSO was added to untreated cells.
We used 3 and 30 g of total proteins for SDS–PAGE and Western blotting to detect the E2-72kDa early protein and penton and fiber, respectively.
Phosphorimager analysis was used to quantify the amount of viral proteins. (C) HeLa cells were infected at 20 FFU/cell of Ad5, H5dl1006 (lacks intact
E4-11kDa), and H5dl1010 (lacks intact E4-34kDa) (left) and 10 FFU/cell Ad5 and H5dl110 (lacks intact E1b-55kDa) (right). Cells were left untreated or
treated from 2–24 hpi with 10 M MG132. Cell extracts were subjected to Western blotting as described in part B. Phosphorimager analysis was used to
quantify the amount of the viral proteins penton and fiber.
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(Stracker et al., 2002). In the absence of these viral regula-
tory proteins, DSBR activities ligate viral DNA genomes to
form concatemers in cells infected with Ad mutants (Boyer
et al., 1999; Weiden and Ginsberg, 1994). These observa-
tions raise the attractive possibility that E4-34kDa may
complement late gene expression by promoting degradation
of DSBR proteins and preventing the formation of DNA
concatemers during viral replication. Alternatively, the E4-
34kDa/E1b-55kDa complex may promote the transition to
the late phase by targeting additional proteins for ubiquiti-
nation and proteasome-mediated degradation. We are cur-
rently performing experiments to address these possibilities.
In our complementation assay, wild-type and mutant
E4-34kDa proteins were expressed from a plasmid construct
under the control of a CMV promoter rather than from the
viral genome. A limitation of this approach is that the
expression of the E4-34kDa protein is not transcriptionally
regulated in the natural context of the E4 promoter. Char-
acterization of E4-34kDa mutants expressed from the E4
promoter during virus infection will be an important exten-
sion for further understanding E4-34kDa function. We have
confirmed the importance of the proteasome for E4-34kDa
function during virus infection when E4-34kDa is expressed
from its own promoter in the viral genome, in infected cells
treated with the proteasome inhibitor MG132 (Fig. 6). Ge-
netic studies indicate that the activity of the E4-34kDa
protein is at least partially redundant with the function of the
E4-11kDa protein (Bridge and Ketner, 1989; Huang and
Hearing, 1989). When cells were infected with Ad5 and
mutants with an intact E4-11kDa protein, MG132 delayed,
but did not block, viral replication and late gene expression
(Fig. 6). However, H5dl1006 late gene expression was more
sensitive to the proteasome inhibitor MG132. H5dl1006
lacks the E4-11kDa gene and relies on the activity of the
E4-34kDa/E1b- 55kDa complex for late gene expression
(Bridge and Ketner, 1989). Our results indicate that while
activity of the E4-34kDa/E1b-55kDa complex depends on
functional proteasomes, E4-11kDa is much less dependent
on proteasome activity to promote late gene expression. It
will be interesting to determine if E4-11kDa-mediated re-
distribution of DSBR proteins and prevention of DNA con-
catemers can still occur in the presence of proteasome
inhibitors.
In summary, our mutational analysis of the E4-34kDa
protein revealed that regions needed to target proteins for
ubiquitination and proteasome-mediated degradation were
also critically important for the ability of E4-34kDa to
complement H5dl1011. We observe that proteasome inhib-
itors interfere with E4-34kDa complementation, and they
dramatically affect late gene expression of a virus that
depends on the function of the E4-34kDa/E1b-55kDa com-
plex because it lacks the redundant functions of the E4-
11kDa protein. Taken together, these results indicate that
proteasome-mediated degradation of target proteins makes
an important contribution to the ability of the E4-34kDa/
E1b- 55kDa complex to promote viral late gene expression.
Materials and methods
Cells and viruses
HEK 293 cells were kindly provided by J. Lingrell (Gra-
ham et al., 1977). HeLa and W162 (Weinberg and Ketner,
1983) monolayer cultures were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, 10
U/mL penicillin, and 10 g/mL streptomycin. H1299 cells
(ATCC CRL 5803) were grown in RPMI 1640 supple-
mented with 10% FBS, 1 mM sodium pyruvate, 10 U/mL
penicillin, and 10 g/mL streptomycin. Wild-type Ad5 vi-
rus was originally obtained from J. Williams and propa-
gated on HeLa and W162 cells. The E1b and E4 virus
mutants H5dl110, H5dl1006, H5dl1010, and H5dl1011
have been described previously (Bridge and Ketner, 1989,
1990). H5dl110 was propagated on HEK 293 cells.
H5dl1006, H5dl1010, and H5dl1011 were propagated on
W162 cells. Virus titers were determined as previously
described (Philipson, 1961) and expressed as fluorescence
forming units per milliliter. Virus titers for Ad5 and
H5dl110 were determined in parallel on HEK 293 cells.
Virus titers for Ad5, H5dl1006, H5dl1010, and H5dl1011
were determined in parallel on W162 cells.
Plasmids
Wild-type Ad5 E4-34kDa cDNA was obtained from T.
Dobner. The gene was PCR amplified with a 5 primer
introducing HindIII and BamHI sites (5- CGCAAGCTT-
GGATCCATGACTACGTCCGGCGTTCCATTTGGC-3)
and a 3 primer that mutated the natural stop codon, and
added an XhoI site, a nine amino acid influenza hemagglu-
tinin (HA) epitope tag (YPYDVPDYA), and a new stop
codon 3 to the HA sequence to the C-terminus (5- CGCC-
TCGAGTCAGCTTGCGTAATCCGGTACATCGTAAG-
GGTACATGGGGGTA GAGTCATAATCGTG-3). Ad5
E4-34kDa PCR products were cloned into pcDNA3.1()
(Invitrogen) under the control of a CMV promoter. N-
terminal deletions were generated by PCR using a 5 primer
engineered with a translation start codon that hybridized 3
to the wild-type start codon at the desired nucleotide with a
HindIII site (dl1–20: 5-CGCAAGCTTACCATGCGGCG-
CACTCCGTACAGTAGGGATCGCC-3; dl1–55: 5-
CGCAAGCTTACCATGCACAACGTGAGTTACGT-
GCGAGGTC-3) and the same 3 primer used for wild-type
E4-34kDa. C-terminal deletions were generated by PCR
using the same 5 primer used for wild-type E4-34kDa
above and a 3 primer that hybridized internal to the transla-
tional stop codon at the desired location. The 3 primer added
the HA tag, a new stop codon to the C-terminus, and an
XhoI site (dl277–294: 5- GCGCTCGAGTCAGCTTGC-
G T A A T C C G G T A C A T C G T A A G G G -
TACGCGCGAATAAACTGCTGCCGCCG-3; dl271–294:
5  - G C G C T C G A G T C A G C T T G C G T A A T C C G G -
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TACATCGTAAGGGTACCGCCGCCGC TCCGTCCTG-
CAGG-3). All Ad5 E4-34kDa deletion mutants were
cloned into pCDNA3.1() and verified by sequencing.
Plasmids with internal deletions of Ad5 E4-34kDa (dl35–
43, dl49–64, dl123–126, dl154–180, and dl249–274) and
the C-terminal deletion dl275–294 were provided by P.
Branton (Querido et al., 2001b). A plasmid with the Ad9
E4-34kDa cDNA was obtained from R. Javier. It was used
as a template for PCR using a wild-type 5 primer engi-
neered with a HindIII site (5- CGCAAGCTTGAATTCAC-
CATGCAAACCGAGATTCAATCCAGC-3) and a 3
primer that changed the wild-type stop codon and added the
HA tag and an XhoI site onto the C’terminus (5- CGC-
CTCGAGTCAGCTTGCGTAATCCGGTACATC-
GTAAGGGTACAGTCTGGTG GAATGAGAAGA-
ACGC-3). A plasmid containing the Ad12 E4 region was
obtained from W. Doerfler and the Ad12 E4-34kDa gene
was PCR amplified with the following N-terminal primer
with a HindIII site (5- CGCAAGCTTGGATCCACCAT-
GCAGCGCGACAGACGGTATCGC-3) and C- terminal
primers with an XhoI site and the C-terminal HA tag (5-
C G C C T C G A G T C A G C T T G C G T A A T C C G G T A -
CATCGTAAGGGTAGTGTCCATCA GCCGCCCAAGG-
3). Ad40 total DNA obtained from C. Tiemessen was used
as a template to PCR amplify the E4-34kDa gene using a 5
primer with an NheI site (5CGCGCTAGCACCATGGA-
AAGGACTCCTGGACTTTTAGAG-3) and a 3 primer
with a BamHI site and the HA tag (5- CGCGGATCCT-
C A G C T T G C G T A A T C C G G T A C A T C G T A A G G -
GTAAGCTCTCCAC GGGTTCTCGCCTCTG-3). Ad9,
Ad12, and Ad40 E4-34kDa genes were cloned into
pcDNA3.1() and verified by sequencing. The pcDNA p53
plasmid was obtained from P. Branton. All plasmids were
transfected into cell lines using the Effectene transfection
reagent (Qiagen) according to the manufacturer’s direc-
tions.
Western blotting analysis
Cells seeded in 35-mm dishes were washed twice with
ice-cold phosphate-buffered saline (PBS) and then lysed in
250–300 L of lysis buffer (150 mM NaCl, 50 mM Tris pH
8.0, 5 mM EDTA, 0.15% [vol/vol] Nonidet P-40, 0.1 mM
DTT, and 5 g/ml aprotinin and leupeptin). Cell lysates
were sonicated and total protein was measured by Bradford
assay using Coomassie Plus protein reagent (Pierce) accord-
ing to manufacturer’s specifications. Equal amounts of total
protein were subjected to sodium dodecyl sulfate–polyac-
rylamide gel electrophoresis (SDS–PAGE) using either 12
or 15% polyacrylamide gels. Proteins were transferred to
enhanced chemiluminescence (ECL) nitrocellulose (Amer-
sham Pharmacia) overnight and the membranes were
probed with primary antibodies diluted in 5% nonfat dry
milk. Antibodies that recognize the HA epitope tag on
wild-type Ad5 E4-34kDa, N-terminal deletions, and E4-
34kDa from Ad9, Ad12, and Ad40 (mouse monoclonal F-7
or rabbit polyclonal Y-11; Santa Cruz Biotechnology) were
diluted 1:200 and 1:250, respectively. E4 ORF6 C-terminal
antibody 1807 (rabbit polyclonal from P. Branton) diluted
1:5000 was also used to detect N-terminal deletions of
E4-34kDa. RSA3 (mouse monoclonal antibody from T.
Shenk) was diluted 1:100 and used to detect wild-type Ad5
E4-34kDa and C-terminal deletions of E4-34kDa. B610
(mouse monoclonal from A. Levine) was diluted 1:100 to
detect E2-72kDa. Rabbit polyclonal antibodies to penton
and fiber (from U. Pettersson) were used at a 1:1000 dilu-
tion. Antibody to p53 (mouse pAb1801; Zymed) was di-
luted 1:250. Protein blots were incubated with horseradish
peroxidase conjugated goat anti-mouse or anti-rabbit IgG
(1:1500) secondary antibodies diluted in 5% nonfat dry
milk. Proteins were visualized by incubating blots with ECL
reagent (Amersham Pharmacia) and the chemiluminescent
signals were captured by Hyperfilm ECL (Amersham Phar-
macia).
Analysis of E4-34kDa and late proteins expression levels
in the complementation assay
Cell extracts from complementation assays were sub-
jected to Western blotting and wild-type and mutant E4-
34kDa and late proteins were detected with the same pri-
mary antibodies described for Western blotting. An alkaline
phosphatase conjugated goat anti- mouse or anti-rabbit IgG
(1:2000) secondary antibody (Sigma) was used and en-
hanced chemifluorescence (ECF) substrate (Amersham)
was used for detection of proteins on a STORM 860
phoshorimager (Molecular Dynamics). Scanned images
were analyzed using ImageQuant 5.2 (Molecular Dynam-
ics) software to quantify the amount of protein. The amount
of E4-34kDa quantified from cultures transfected with in-
creasing amounts (0.25–2.0 g) of wild-type E4-34kDa
plasmid was plotted against the amount of late proteins
detected in the respective cell extracts to generate a wild-
type E4-34kDa complementation standard curve for every
replicate experiment. Complementation by mutant E4-
34kDa proteins was determined by normalizing comple-
mentation for the amount of mutant E4-34kDa expressed
relative to wild-type E4-34kDa. This was done by extrapo-
lating the amount of E4-34kDa mutant protein expressed
onto the wild-type E4-34kDa standard curve to determine
the expected amount of late proteins relative to the amount
of E4-34kDa expressed. This extrapolated value was then
compared to the actual amount of late proteins quantified in
the mutant E4-34kDa complementation assay. If the ex-
pected amount of late proteins was equal to the actual
amount expressed in the mutant complementation assay,
complementation by the mutant was 100% of wild-type.
Viral DNA analysis
HeLa cells seeded onto 35-mm dishes were infected with
20 FFU/cell of Ad5 virus in the presence or absence of 10
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M MG132. Total DNA was isolated as described (Bridge
and Ketner, 1989). Ten micrograms of total DNA from each
sample was digested with EcoRI and subjected to electro-
phoresis in a 1% agarose gel for 20 h at 22 V. DNA was
transferred to Hybond-N nylon membrane (Amersham) ac-
cording to the manufacturer’s specifications. 32P-labeled
Ad2 DNA was synthesized using the Multiprime DNA
labeling system (Amersham). Hybridization was performed
at 65°C for 20 h as described (Sambrook et al., 1989). The
amount of viral DNA was measured by phosphorimager
analysis. Scanned images were analyzed using ImageQuant
5.2 (Molecular Dynamics) software to quantify amount of
DNA.
Proteasome inhibitors
In experiments where proteasome inhibitors were used,
10 M MG132 (Calbiochem), 10 M lactacystin (Calbio-
chem), or 10 M clasto-lactacystin - lactone (BostonBio-
chem) dissolved in DMSO (Sigma) was added at the indi-
cated times posttransfection or infection. DMSO was added
to control cells not treated with the inhibitors.
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